Improvement of therapeutic compliance in haemodialysis patients with poor phosphorus control and adherence to treatment with binders: COMQUELFOS study

Nefrologia

Volumn 33, Issue 2, 2013, Pages 196-203

  Dolores Arenas, M ^a   Pérez García, Rafael ^b   Bennouna, Mazine ^c   Blanco, Ana ^d   Mauricio Reatiga, Óscar ^e   Prados, M Dolores ^f   Lerma, José L ^g   Muñiz, M Luisa ^h   Belen Martin M ⁱ  

^a HOSPITAL PERPETUO SOCORRO   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^c Edificio Polivalente   (Spain)

^d Hemodialysis Unit   (Spain)

^e Fresenius Medical Care   (Spain)

^f HOSPITAL TORRECÁRDENAS   (Spain)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h HOSPITAL DE CRUCES   (Spain)

ⁱ Centro de Diálisis Los Enebros Fresenius Medical Care   (Spain)

Author keywords

Adherence; Haemodialysis; Phosphate binders; Phosphatemia; Phosphorus; Therapeutic compliance

Indexed keywords

CHELATING AGENT; PHOSPHORUS;

ADULT; AGED; ARTICLE; FEMALE; FOLLOW UP; HUMAN; HYPERPHOSPHATEMIA; MALE; MEDICATION COMPLIANCE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; QUESTIONNAIRE; RENAL REPLACEMENT THERAPY; STATISTICS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHELATING AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPHOSPHATEMIA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHOSPHORUS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RENAL DIALYSIS; YOUNG ADULT;

EID: 84875821410     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2012.Oct.11726     Document Type: Article

References (19)

1. Wei M, Taskapan H, Esbaei K, Jassal SV, Bargman JM, Oreopoulos DG. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them? Int Urol Nephrol 2006;38:739-43.
2. Rodríguez-Benot A, Martín-Malo A, Álvarez-Lara MA, Rodríguez M, Aljama P. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis 2005;46(1):68-77.
3. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-87.
4. Lorenzo V, Martín-Malo A, Pérez-García R, Torregrosa JV, Vega N, De Francisco AL, et al. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study. Nephrol Dial Transplant 2006;21(2):459-65.
5. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and PracticePatterns Study (DOPPS). Am J Kidney Dis 2008;52(3):519-30.
6. Pérez-García R, Albalate M, de Sequera P, Alcázar R, Puerta M, Ortega M, et al. La hemodiafiltración en línea mejora la respuesta al tratamiento con calcifediol. Nefrologia 2012;32(4):459-66.
7. Tentori F, Zhang J, Li Y, Karaboyas A, Kerr P, Saran R, et al. Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2012;27(11):4180-8.
8. Arenas MD, Malek T, Alvarez-Ude F, Gil MT, Moledous A, Reig- Ferrer A. Captores del fósforo: preferéncias de los pacientes en hemodiálisis y su repercusión sobre el cumplimiento del tratamiento y el control del fósforo. Nefrologia 2010;30(5):522-30.
9. Karamanodou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 2008;9:2.
10. Knobel H, Alonso J, Casado JL, Collazos J, González J, Ruiz I, et al. GEEMA Study Group. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA study. AIDS 2002;16:605-13.
11. Ortega Suárez FJ, Sánchez Plumed J, Pérez Valentín MA, Pereira Palomo P, Muñoz Cepeda MA, Lorenzo Aguiar D; Grupo de Estudio Vatren. Validación del cuestionario simplificado de adherencia a la medicación (SMAQ) en pacientes con trasplante renal en terapia con tacrolimus. Nefrologia 2011;31(6):690-6.
12. Arenas MD, Malek T, Gil MT, Moledous A, Álvarez-Ude F, Reig- Ferrer A. The challenge of phosphorus control in the hemodialysis patient: a problem of adherence? J Nephrol 2010;23(5):525-34.
13. Leggat JE Jr, Orzol SM, Hulbert-Shearon TE, Golper TA, Jones CA, Held PJ, Port FK. Noncompliance in hemodialysis: predictors and survival analysis. Am J Kidney Dis 1998;32(1):139-45.
14. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000;35(6):1226-37.
15. Holley JL, DeVore CC. Why all prescribed medications are not taken: results from a survey of chronic dialysis patients. Adv Perit Dial 2006;22:162-6.
16. Ramos R, Alcazar R, Otero A, De Francisco ALM, Del Pino MD. Impacto económico del tratamiento con vitamina D en pacientes con enfermedad renal crónica. Nefrologia 2011;31(5):528-36.
17. Karamanidou C, Weinman J, Horne R. Improving haemodialysis patients' understanding of phosphate-binding medication: a pilot study of a psycho-educational intervention designed to change patients' perceptions of the problem and treatment. Br J Health Psychol 2008;13(Pt 2):205-14.
18. Costantini L. Compliance, adherence, and self-management: is a paradigm shift possible for chronic kidney disease clients? CANNT J 2006;16(4):22-6.
19. Ashurst Ide B, Dobbie H. A randomized controlled trial of an educational intervention to improve phosphate levels in hemodialysis patients. J Ren Nutr 2003;13(4):267-74.